Reactivating p53 mutants selectively in patients

Shuo Chen; H Michael Shepard; Min Lu

doi:10.1016/j.ccell.2026.03.009

Reactivating p53 mutants selectively in patients

Cancer Cell. 2026 Apr 13;44(4):715-717. doi: 10.1016/j.ccell.2026.03.009. Epub 2026 Apr 2.

Authors

Shuo Chen¹, H Michael Shepard², Min Lu³

Affiliations

¹ Shanghai Immune Therapy Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
² Frontiers in Therapeutics Research Center, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
³ Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: min.lu@shsmu.edu.cn.

PMID: 41932331
DOI: 10.1016/j.ccell.2026.03.009

Abstract

As the most frequently mutated protein across cancers, the tumor suppressor protein p53 is inactivated by the most extensive array of different mutations. Targeting a frequent p53 mutant with the reactivator rezatapopt, recent findings published in the New England Journal of Medicine mark an encouraging step toward clinical utility.

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Humans
Mutation*
Neoplasms* / drug therapy
Neoplasms* / genetics
Tumor Suppressor Protein p53* / genetics
Tumor Suppressor Protein p53* / metabolism

Substances

Tumor Suppressor Protein p53
TP53 protein, human
Antineoplastic Agents